Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Cytosolic Delivery of Tumor Antigens into Dendritic Cells

Award Number: F32CA239362
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 01/01/2020
PERIOD OF PERFORMANCE END DATE: 08/12/2022

Group Awards By:

View Award Description

Cytosolic Delivery of Tumor Antigens into Dendritic Cells - PROJECT SUMMARY/ABSTRACT Cancer vaccines have recently emerged as a selective way to activate T cells against cancer. The treatments are based on peptides, called tumor antigens, derived from peptide sequences in tumors that are immunogenic. Another class of tumor antigens, called neoantigens, arise from mutations in tumors that have not been detected by the immune system. These cancer vaccines with tumor antigens or neoantigens can promote antigen-specific, rather than nonspecific, T-cell activation, by either generating new or amplifying existing immune responses against tumors. Despite the promising anti-cancer immune responses observed with these treatments, effective and selective activation of the immune system remains difficult. Several challenges have limited the translation of cancer vaccines into the clinic: (1) Sufficient uptake of the antigens by antigen presenting cells is difficult to achieve, which greatly influences whether the peptides are processed or presented to T cells. (2) Proteasomal processing of the peptides is difficult to predict, which can result in the formation of peptide fragments, other than the desired antigen, that neither bind to an HLA allele nor activate an immune response. Antigen delivery systems can play crucial roles in improving cancer vaccines. The delivery systems can perform two critical functions, which the absence of currently limits the efficacy of cancer vaccines: promote targeting to dendritic cells (DCs) and facilitate cytosolic delivery. This proposal describes the development of an anthrax delivery system for delivering tumor antigens. My overarching hypothesis is that the anthrax machinery is well suited for delivering tumor antigens, because it can efficiently perform protein translocation. In nature, the delivery system transports toxins into the cell cytosol that rapidly induce cell death. The main components are easily modified for transporting non-native cargo into cells, including therapeutic peptides, proteins, and even small molecules. This proposal will develop the anthrax delivery system with two new features: to target dendritic cells and to deliver tumor antigens. These features will be developed to enhance tumor antigen activity in vivo (Aim 1) and to shed light on antigen processing and presentation (Aim 2). The impact of this work will extend beyond developing an effective tool for tumor antigen delivery. It will also facilitate the identification and study of tumor antigens selective for T cell activation, which will ultimately lead to the development of better tumor antigens for cancer vaccines in the clinic and beyond. The training plan and environment permits the design and study of the anthrax delivery system with the Pentelute lab (MIT), Irvine lab (Koch Institute for Integrative Cancer Research at MIT), and Wu lab (Dana- Farber Cancer Institute). The proposed studies will be performed with the equipment and resources available in these labs, and with the facilities available at the Swanson Biotechnology Center at the Koch Institute.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$28,652 )
2023	2022	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Cancer Research Manpower	000	3	1/25/2023	NON-COMPETING CONTINUATION	-$22,182
2023	2022	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Cancer Research Manpower	001	3	6/20/2023	NON-COMPETING CONTINUATION	-$6,470
														Subtotal = -$28,652

Issue Date FY: 2022 ( Subtotal = $69,802 )
2022	2022	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Cancer Research Manpower	001	3	5/20/2022	NON-COMPETING CONTINUATION	$1,240
2022	2022	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Cancer Research Manpower	000	3	11/18/2021	NON-COMPETING CONTINUATION	$68,562
														Subtotal = $69,802

Issue Date FY: 2021 ( Subtotal = $66,390 )
2021	2021	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Cancer Research Manpower	000	2	11/4/2020	NON-COMPETING CONTINUATION	$65,310
2021	2021	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Cancer Research Manpower	001	2	2/3/2021	NON-COMPETING CONTINUATION	$1,080
														Subtotal = $66,390

Issue Date FY: 2020 ( Subtotal = $64,926 )
2020	2020	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Cancer Research Manpower	002	1	2/11/2020	NEW	$3,700
2020	2020	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Cancer Research Manpower	000	1	12/9/2019	NEW	$61,226
2020	2020	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Cancer Research Manpower	001	1	12/9/2019	NEW	$0
														Subtotal = $64,926

Grand Total All Awards = $172,466

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Cytosolic Delivery of Tumor Antigens into Dendritic Cells

Award Number: F32CA239362

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 01/01/2020

PERIOD OF PERFORMANCE END DATE: 08/12/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer